Companion@360 → 7 Month programme to sharpen your writing skills → REGISTER NOW
Pfizer vaccine
The US and Europe are in line to get the first doses of an experimental coronavirus vaccine after a partnership between Pfizer Inc. and BioNTech SE delivered dazzling preliminary results in a large patient trial.
Regulators on both sides of the Atlantic ocean are working to speed a review of the shot’s safety and effectiveness after the data showed it prevented more than 90% of infections
BNT162b1 or BNT162b2 — have gone into human trials so far. Both are in Phase 1/2 human trials in the United States and Germany.
BNT162b2 was associated with less systemic reactogenicity, particularly in older adults. This effectively means that BNT162b2 generates an even lower adverse reaction among the vulnerable population, making it the safer candidate of the two.
The researchers announced that after an extensive review of preclinical and clinical data and in consultation with the US FDA’s Center for Biologics Evaluation and Research, they have chosen to advance their BNT162b2 vaccine candidate into the Phase 2/3 study, where 30,000 participants will be taking part.
Read Indian SARS-CoV-2 Genomic Consortia (INSACOG)